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The antimalarial activity and pharmacology of a series of phenylthiazolyl-bearing hydroxamate-based
histone deacetylase inhibitors (HDACIs) was evaluated. In in vitro growth inhibition assays approximately 50
analogs were evaluated against four drug resistant strains of Plasmodium falciparum. The range of 50%
inhibitory concentrations (IC50s) was 0.0005 to >1 M. Five analogs exhibited IC50s of <3 nM, and three of
these exhibited selectivity indices of >600. The most potent compound, WR301801 (YC-2-88) was shown to
cause hyperacetylation of P. falciparum histones, which is a marker for HDAC inhibition in eukaryotic cells.
The compound also inhibited malarial and mammalian HDAC activity in functional assays at low nanomolar
concentrations. WR301801 did not exhibit cures in P. berghei-infected mice at oral doses as high as 640
mg/kg/day for 3 days or in P. falciparum-infected Aotus lemurinus lemurinus monkeys at oral doses of 32
mg/kg/day for 3 days, despite high relative bioavailability. The failure of monotherapy in mice may be due to
a short half-life, since the compound was rapidly hydrolyzed to an inactive acid metabolite by loss of its
hydroxamate group in vitro (half-life of 11 min in mouse microsomes) and in vivo (half-life in mice of 3.5 h after
a single oral dose of 50 mg/kg). However, WR301801 exhibited cures in P. berghei-infected mice when combined
at doses of 52 mg/kg/day orally with subcurative doses of chloroquine. Next-generation HDACIs with greater
metabolic stability than WR301801 may be useful as antimalarials if combined appropriately with conventional
antimalarial drugs.
Considerable research activity has focused on understanding
the “histone code,” and in particular on the design of hydrox-
amate-based histone deacetylase inhibitors (HDACIs) as novel
therapeutics for the treatment of a wide range of disorders,
including cancer and neurodegenerative diseases (26). HDACIs
owe their action to their ability to reactivate silenced genes by
modulating the condensation status of DNA. The posttransla-
tional acetylation status of chromatin is determined by the
competing activities of two classes of enzymes, histone acetyl-
transferases (HATs) and histone deacetylases (HDACs) which
control the acetylation of lysine residues on histone tails. In
general, HATs function to acetylate lysine groups in nuclear
histones, resulting in neutralization of the charges on the his-
tones and a more open, transcriptionally active chromatin
structure, while the HDACs function to deacetylate and sup-
press transcription. A shift in the balance of acetylation on
chromatin may result in changes in the regulation of patterns
of gene expression (16, 24, 37, 39). Since many cancers are
associated with aberrant transcriptional activity, and HDACs
can affect transcription factors and gene regulation, these en-
zymes have been identified as attractive targets for cancer
therapy. Indeed, chemical inhibitors of HDACs have been
shown to inhibit tumor cell growth and induce differentiation
and cell death (28). Several such inhibitory agents, including
suberoylanilide hydroxamic acid (SAHA) and depsipeptide
(FR901228) have reached clinical trials (6, 20, 35), and SAHA
has been approved by the U.S. Food and Drug Administration
for use in treating cutaneous T-cell lymphoma. HDACIs are
thought to function by allowing the transcription and expres-
sion of genes, including tumor suppressor genes. HDACIs
also enhance the cytotoxic effects of therapeutic agents used
in cancer treatment, including radiation and chemothera-
peutic drugs (25, 27).
Initial studies suggest that HDAC may be an attractive tar-
get in P. falciparum. The antimalarial activity of HDACIs was
first reported by Darkin-Rattray et al. (11). Apicidin, a fungal
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metabolite, was found to exhibit an MIC of 125 ng/ml against
P. falciparum and exhibited a suppressive effect on blood-stage
parasites when administered intraperitoneally at a dose rate of
50 mg/kg in mice. Functional studies suggested that the target
of apicidin was indeed malarial HDAC. The compound did not
appear to have much selectivity for malaria, since its 50%
inhibitory concentration (IC50) against proliferating mamma-
lian cells was 50 to 100 nM. Subsequently, Joshi et al. (18)
cloned an HDAC directly from P. falciparum (HDAC-1) and
showed that it localized in the parasite nucleus and was ex-
pressed primarily in mature asexual blood stages and gameto-
cytes. A subsequent study (2) also demonstrated that other
putative HDACIs were active in vitro and in vivo. These stud-
ies suggest that HDAC is a promising target. However, these
initial findings have not yet been properly exploited in order to
develop potential antimalarial drugs for clinical use. Recently,
our research groups reported that certain triazolylphenyl (9)-
and 2-aminosuberic acid (1)-based hydroxamates have nano-
molar potency against drug-resistant strains of P. falciparum in
vitro. We have also reported the synthesis and screening of
phenylthiazolyl-based hydroxamate inhibitors as agents against
pancreatic cancer (21). Here we report that this same group of
compounds exhibits the most potent and selective antimalarial
activity of all of the HDACIs tested thus far.
MATERIALS AND METHODS
Synthesis of HDACIs. Approximately 50 phenylthiazolyl-hydroxamate-based
HDACIs were synthesized. Those with IC50s 10 nM (C2A strain) or with IC50s
100 nM that revealed useful information about structure activity relationships
are shown in Table 1. Synthetic schemes and characterization data are presented
as Fig. S1 and S2 and Table S1 in the supplemental material, respectively.
Compounds are referred to by their WR designations throughout (the original
laboratory designations have been left associated with the characterization data
in Table S1 in the supplemental material).
In vitro susceptibility and toxicity assays. The in vitro activities of HDACIs
against P. falciparum strains W2, D6, TM91C235, and TM90C2A were evaluated
by using the labeled hypoxanthine assay of Desjardins et al. (12) as modified by
Milhous et al. (30) and described in one of our earlier reports (14). W2 is
chloroquine resistant and mefloquine sensitive, D6 is chloroquine sensitive but
naturally less susceptible to mefloquine, and TM91C235 is resistant to
mefloquine, chloroquine, and pyrimethamine, as is TM90C2A; however, this
latter parasite is a two pfmdr1 copy strain. The data for WR301801, WR308298,
WR308291, WR308296, and WR308294 against the D6, W2, and C235 strains
are reported as the averages of duplicate IC50s in Table 1. The remaining IC50s
for other compounds against all strains are reported as single values for each
compound in Table 1. We routinely run mefloquine and chloroquine as controls
to ensure assay validity. The IC50s and standard deviations of chloroquine and
mefloquine (for the last 15 assays) for each strain are reported in Table 1.
Selectivity was defined at the cellular rather than enzymatic level (see Discus-
sion). Selectivity was assessed by first determining the LC50s of three of the five
most potent compounds against macrophages (RAW cell line) using the 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as de-
scribed in one of our earlier studies (7). Selectivity indices were determined by
using the following formula: 50% lethal concentration (LC50) (RAW cells)/IC50
(P. falciparum).
Histone hyperacetylation assay. The effect of compounds on P. falciparum
histone acetylation status was determined as previously described (1). Approxi-
mately 3  109 late-trophozoite-stage 3D7-infected erythrocytes (a mefloquine-
resistant clone of W2) were incubated with different concentrations of com-
pounds or vehicle alone (0.01% dimethyl sulfoxide) for 3.5 h at 37°C, before
histones were prepared. An additional untreated control sample was taken at the
start of the assay. Histone extracts (ca. 6 108 parasites per lane) were separated
by sodium dodecyl sulfate–15% polyacrylamide gel electrophoresis (SDS–15%
PAGE), and equal loading was confirmed using silver staining. To detect changes
in acetylation patterns after treatment, SDS-PAGE separated samples were
transferred to a polyvinylidene difluoride membrane (Roche) at 80 V for 1 h in
25 mM Tris-HCl–0.2 M glycine–20% methanol. Membranes were blocked in
phosphate-buffered saline (PBS) containing 3% skim milk powder for at least 1 h
before anti-(tetra)acetyl H4 histone antibody or anti-(di)acetyl-H3 antiserum
(Upstate; 1:2,000 dilution in PBS–3% skim milk powder) was added, followed by
incubation for 2 h at room temperature. After three washes in deionized water,
the membranes were incubated for 1 h in goat anti-rabbit antibody conjugated to
horseradish peroxidase (Zymed; 1:5,000 dilution in PBS–3% skim milk powder).
The membranes were washed again, and signal was detected with enhanced
chemiluminescence (GE Healthcare, United Kingdom) and autoradiography.
The same membrane was then stripped and rehybridized with anti-(di)acetyl-H3
antisera (Upstate; 1:2,000 dilution in PBS–3% skim milk powder) using the
conditions described above.
Functional HDAC assay. The effect of WR301801 on malarial and mammalian
HDAC was evaluated by using a commercially available fluorometric activity
assay in 96-well plates according to the manufacturer’s instructions (kit AK-503;
Biomol International) as follows. For the mammalian assay, confluent Vero cells
were used. Approximately 106 isolated parasites (W2, late trophozoites) were
used for the malaria assay. Cells were incubated with a cell-permeable substrate
(Fleur de Lys) for 3 to 4 h. During this time the substrate accumulates intracel-
lularly and is deacetylated. After incubation, the cells were treated for 20 min
with a developer. This generates a fluorescent signal from the deacetylated
substrate and induces cell lysis. Plates were read in a Tecan fluorescence reader
(excitation, 350 to 380 nm; emission, 440 to 460 nm). HDAC inhibition is
manifested as a reduction in the arbitrary fluorescence units relative to drug-free
controls. Each drug concentration was tested in triplicate at least twice. Tricho-
statin A was used as a control in the mammalian assay and exhibited the expected
results (data not shown).
In vitro isobologram studies. The in vitro drug combination activity of
HDACIs with known antimalarial drugs against P. falciparum strains W2 and D6
were evaluated by using the malaria Sybr green I fluorescence-based assay of
Smilkstein et al. (36) and as described in one of our earlier studies (17). Briefly,
each antimalarial drug was tested alone and at fixed ratios with 12 twofold serial
dilutions. The starting concentration (for serial dilutions across the microtiter
plate) was assigned so that the IC50 of each drug would be in the center of the
plate. The IC50s were calculated for each drug alone and for their respective
fixed concentration ratios. The IC50s of drug A and drug B were standardized by
allocating a value of 1 to each drug that was tested alone and pro rata values for
each fixed concentration ratio. The individual and sum 50% fractional inhibitory
concentrations (FIC50 and FIC50, respectively) were determined as described
by Berenbaum (3). Isobolograms were constructed from the FIC50s of drug A
and drug B at different fixed concentration ratios: a straight line represents
additivity (FIC  1), a concave line denotes a trend toward synergy (FIC 
1) or synergy (FIC  0.5), and a convex curve represents a trend toward
antagonism (FIC  1) or antagonism (FIC  2). The data are reported here
as the average FIC (across all drug dilutions) or the average maximum FIC
at any dilution for at least two replicate experiments for each drug combination.
In vivo efficacy studies. The antimalarial activity of WR301801 alone and in
combination with chloroquine against blood stage Plasmodium berghei in mice
and P. falciparum in Aotus lemurinus lemurinus monkeys was evaluated as de-
scribed by us in an earlier publication (13). Briefly, in the mouse assay, all mice
were inoculated intraperitoneally with 106 P. berghei-parasitized erythrocytes.
WR301801 (0.32 to 640 mg/kg/day for 3 days) alone or in combination with
chloroquine at subtherapeutic doses (2 to 64 mg/kg/day for 3 days) orally once
per day on days 3, 4, and 5 postinfection in a hydroxethylcellulose-Tween 20
vehicle (n  5 mice per dose group). Blood smears were obtained on study days
0, 3, 6, 10, 13, 17, 20, 24, 27, and 31. The efficacy was assessed by monitoring
intermittently the effect of the drugs on parasitemia and cure rates. A cure was
defined as the absence of microscopic parasites in blood smears without his-
topathological evidence of malaria infection on day 31 postinfection. In other
experiments WR301801 was given subcutaneously or over 7 days. In the Aotus
studies, the five monkeys selected for the study had active infections of the
chloroquine-resistant FVO strain of P. falciparum. The animals had previously
been treated unsuccessfully with a single 25-mg/kg dose of an experimental
quinoline methanol. Once parasitemias reached 5,000/l (or as deemed appro-
priate by the attending veterinarian), they were treated orally with WR30801 at
8, 16, or 32 mg/kg/day for 3 days. When these treatments failed they were rescued
with a single 20-mg/kg dose of mefloquine orally). The Aotus monkeys were
cared for and maintained at Gorgas Memorial Institute Aotus colony as previ-
ously described (34). All animal experiments were conducted in compliance with
the Animal Welfare Act and other federal statutes and regulations relating to
animals and experiments involving animals and adhere to principles stated in the
Guide for the Care and Use of Laboratory Animals (32).
Metabolism-pharmacokinetic studies. The half-life of WR30801 in mouse and
human liver microsomes was determined as described in our earlier study (13).
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TABLE 1. IC50s and RI values for selected HDACIs against four drug-resistant strains of P. falciparum
Drug or WRAIR no. Structure Mol wt
IC50 (nM)a
RIb
D6 W2 C235 C2A
Mefloquine 11 5.6 5.9  2.1 42  23 46  22 7.8
Chloroquine 14 6 405  206 138  71 189  46 27.0
SAHA WR308364 264 246.6 160.9 309.5 109.7 2.8
301801 362 0.8 1.6 1.5 0.6 2.8
308298 436 0.8 1.0 1.0 0.9 1.3
308291 393 0.9 1.2 1.0 1.0 1.4
308296 397 1.7 1.7 1.4 1.6 1.3
308294 363 2.7 2.7 1.7 1.6 1.7
308301 380 5.1 5.0 2.4 3.8 2.1
308367 377 8.0 7.2 6.1 4.0 2.0
308293 398 3.3 6.4 3.1 5.9 2.0
308292 362 3.9 7.5 3.6 6.0 2.1
308288 353 7.5 17.0 6.5 7.4 2.6
301805 365 11.8 14.2 15.8 7.7 2.0
301839 347 11.8 13.4 16.7 8.8 1.9
301808 388 9.7 17.8 19.3 8.8 2.0
301871 362 9.8 9.4 19.6 9.9 2.1
308295 378 14.9 11.3 6.2 10.3 2.4
301803 391 30.5 35.7 60.8 18.5 3.3
301849 346 33.2 69.8 42.2 28.0 2.5
301826 362 34.2 38.7 41.9 30.3 1.4
Continued on following page
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Drug interaction potential was evaluated in vitro by using BD Gentest (Franklin
Lakes, NJ) CYP450 inhibition kits as recommended by the manufacturer. Plasma
stability was determined by individually incubating the compounds for 0, 1, and
2 h at room temperature and 37°C using a lab rocker and a water bath, respec-
tively, set at 90 rpm. The data were compared to similarly treated acetonitrile-
water samples. Plasma samples were extracted and analyzed as described for the
pharmacokinetic studies below. In the pharmacokinetic studies, WR301801 was
administered as a single dose orally and subcutaneously at a dose of 50 mg/kg to
three groups of six 8-week-old male ICR mice for each dosing route. At 15, 30,
and 60 min and at 3, 6, and 24 h, one mouse from each group (six mice total) was
sacrificed, and plasma was collected and frozen at 80°C. Plasma proteins were
precipitated by adding 2 volumes of acetonitrile to 100-l plasma samples,
followed by high-speed vortexing for 10 to 12 s and centrifugation at 13,000 rpm
for 10 min at 4°C. Then, 5 l of the undisturbed supernatants was analyzed
by liquid chromatography-tandem mass spectrometry (LEAP Technologies,
Carrboro, NC, and ThermoFissher, Waltham, MA) based on standard curves of
WR301801 and WR308301 in the range of 0 to 500 ng/ml and quality controls (10
and 100, n  4 each) prepared by serial dilutions using blank plasma. Samples
were chromatographically separated using a shallow acetonitrile-water gradient
ran trough a 3.5-m, 2.1-by-50-mm, C-18 XTerra MS column from Waters
(Milford, MA) at a flow rate of 0.3 ml/min. Quantification was done by using the
Excalibur (ThermoFisher) software. For the purposes of determining pharma-
cokinetic parameters, each group of six mice was considered to be a single
“animal.” Plasma concentration-time data for WR301801 for each animal were
fitted to a two-compartment open model using a nonlinear, extended least-
squares fitting procedure (WinNonlin 5.1; Scientific Consulting, Inc., Apex, NC)
using weighted (1/concentration) nonlinear regression. The area under the curve
(AUC) was determined by the linear trapezoidal rule with extrapolation to
infinity based on the concentration of the last time point divided by the terminal
rate constant. Extrapolations to time zero were done using zero concentration
for oral or subcutaneous dosing and using C0 values determined from the two-
compartment model equation at time zero. The elimination half-life (t1/2) was
calculated as ln(2)Vss/Vmax[KmC]. Cmax and Tmax were determined individually
for each “animal.” Cmax and Tmax were determined individually for each “ani-
mal.” For WR308303, the AUC was determined after fitting plasma-concentra-
tion time curves to a noncompartmental model. Significant inter-“animal” vari-
ability prevented the determination of other pharmacokinetic parameters.
RESULTS
In vitro antimalarial activity and SAR. The IC50s of the 50
phenylthiazolyl hydroxamates against four strains of P. falcip-
arum spanned a range of 0.5 to 1,000 nM. The data for
the analogs with IC50s of 10 nM and the analogs that
reveal useful information about structure-activity relationships
(SAR) are presented in Table 1. The most potent compounds
(IC50s  3 nM) were all substituted at the meta position of the
phenyl ring with an amino or hydroxyl group. Using these
analogs as a baseline, one can gauge a general impression of
the SAR. Introduction of an amino group at the meta position
of the terminal phenyl ring imparts greater potency than if the
same substitution is made at the ortho or para position (com-
pare WR301801 to WR301871, WR301826, and WR301839,
Table 1). Potency is lost if the meta substituent is a tertiary
amine, methyl, or methoxy group rather than an amino or
hydroxyl group (compare WR301801 and WR308295 with
WR301803, WR308292, and WR308294, Table 1). Other
terminal ring systems could probably be substituted without
loss of potency (compare WR308293 and WR308288 to
WR301839). In the linker region, reduction of the linker
length, substitution or rearrangement of the central amide
bond reduces potency (compare WR301801 to WR301861,
WR301858, and WR301872). Finally, substitution of non-
thiazole ring systems generally reduces potency (compare
WR301801 with WR301849 and WR301871 with WR308369,
Table 1), although some of these alternative compounds are
still more active than SAHA or other antimalarials. Different
HDACIs appear to have different patterns of activity across
the four malaria strains tested (e.g., compare WR301801 with
WR308294), and there does not appear to be a shared pattern
of cross-susceptibility with mefloquine and chloroquine (Table
1). The average resistance index (RI, highest IC50/lowest IC50)
for the HDACI in Table 1 was 2.4 (range, 1.3 to 7.4), whereas
those of mefloquine and chloroquine were 7.4 and 27, respec-
tively.
In vitro cytotoxicity and selectivity indices. The cytotoxicity
of three of the five most potent compounds was evaluated
against RAW macrophage cells. As outlined in Table 2, the SI
was 600 in all cases. A similar LC50 (950 nM) was observed
against Vero cells (data not shown). For WR301801 we ob-
served similar trends in Vero cells (data not shown) and with
a variety of other cell lines in our earlier studies (21, 23). The
LC50s of WR301801 (and corresponding SI values relative to
TABLE 1—Continued
Drug or WRAIR no. Structure Mol wt
IC50 (nM)a
RIb
D6 W2 C235 C2A
308369 423 59.2 63.9 49.7 30.8 2.1
301861 348 12.7 15.8 94.3 34.4 7.4
301872 362 42.4 39.5 170.5 60.7 4.3
301858 401 58.5 72.1 149.6 79.7 2.6
308303c 348 1,400 1,400 1,400 1,400 NA
a Means  the standard deviation are given where applicable.
b That is, the ratio of the highest to the lowest IC50. NA, not applicable.
c A metabolite of WR301801.
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P. falciparum) are lower against the specific pancreatic cancer
cells against which this series was originally optimized (21, 23).
WR301801 (YC-2-88) alters histone acetylation in P. falcip-
arum parasites. Histone hyperacetylation is the marker of
HDAC inhibition in eukaryotic cells, including Plasmodium
spp. (1, 11, 15, 19). The natural product derivative apicidin and
synthetic hydroxamic acid-based HDACIs based on 2-amino
suberic acid cause hyperacetylation of P. falciparum histones
(1, 11) and, conversely, the HAT inhibitor curcumin hypo-
acetylates P. falciparum histone H3 (10). Here we demonstrate
that WR301801 also alters P. falciparum histone acetylation
profiles (Fig. 1). After treatment with WR301801 for 3.5 h, an
increase in acetylated histone-H3 and -H4 was detected using
anti-(di)acetyl H3 and anti-(tetra)acetyl H4 antibodies, respec-
tively. The anti-(tetra)acetyl H4 antibody recognizes a major
species at ca. 12 to 13 kDa in control sample lanes, which
corresponds to histone H4. In samples treated with WR301801
an increase in the intensity of this band is observed, as well as
additional higher-molecular-weight species, one of which likely
corresponds to H2A.Z since the anti-acetyl H4 antibody is
known to cross-react with histone H2 (Fig. 1, indicated by an
arrow) (29). The anti-(di)acetyl H3 antibody recognizes a sin-
gle band at 	15 kDa in all samples, with increased intensity in
samples treated with WR301801. The altered acetylation pro-
files observed after WR301801 treatment occurred at concen-
trations ranging from the approximate IC50 (1 nM) to 1,000
times the IC50 (1,000 nM). Although WR301801 concentra-
tions of 10 nM or higher resulted in complete killing of P.
falciparum parasites, cultures treated with 1 nM WR301801 for
3.5 h that were washed and returned to culture showed 	40%
growth compared to matched controls after 48 h (data not
shown). No change in the histone acetylation profile was ob-
served for infected erythrocytes treated with the 	IC50 of
artemisinin (1.8 nM; Fig. 3) or 1,000 nM (data not shown).
Altered histone acetylation profiles were obtained for the
HDACI control trichostatin A (100 nM) and for another
HDACI SAHA at 10, 100, and 2000 nM (SAHA IC50 of 	100
nM), although at 1 nM the acetylation state returned to that of
controls. These observations were confirmed in an indepen-
dent functional assay in which WR301801 was found to inhibit
parasite HDAC activity in a concentration-dependent manner
with an IC50 in the range of 1 to 10 nM (Fig. 2). WR301801
exhibited an IC50 of 10 nM in the mammalian HDAC inhi-
bition assay (Fig. 2), confirming the results of earlier studies
(9, 23).
In vivo efficacy of WR301801 as monotherapy in mice and A.
lemurinus lemurinus. WR301801 as the most potent and selec-
TABLE 2. Cytotoxicity and selectivity of selected HDACIs
Compound
Lowest IC50
(nM) for
P. falciparum
Mean RAW cell LD50
(nM) (range, n)a
SI (RAW
cells)
SAHA (WR308364) 110 2,200 (1,700–2,700, 2) 22
WR301801 0.59 600 (170–840, 4) 1,080
WR308298 0.81 540 (460–620, 2) 670
WR308291 0.9 3,200 (2,500–3,800, 2) 3,560
a n, number of experiments.
FIG. 1. Hyperacetylation of P. falciparum histones. P. falciparum-
infected erythrocytes (3D7) were cultured in vitro with different con-
centrations of control HDACIs (trichostatin A [TSA] and SAHA), the
antimalarial control artemisinin (ART), or WR301801. Controls were
taken at the start of the experiment (Control [Start]), and a sample was
matched to the treatment groups that received the vehicle alone (Con-
trol, 0.1% dimethyl sulfoxide). Infected erythrocytes were treated with
the indicated concentration of compound for 3.5 h before extraction of
histones and separation via SDS–15% PAGE. Histones were detected
by Western blotting using membranes probed with anti-(tetra)acetyl-H4
and anti-(di)acetyl-H3 antisera. Silver staining was carried out as a
loading control. The arrow indicates histone H2A.Z that is recognized
by the anti-(tetra)acetyl-H4 antibody.
FIG. 2. Activity of WR301801 and artemsinin on malarial (A) and
mammalian (B) HDAC activity. The vertical axes represent arbitrary
fluorescence units (AFU) reflecting the degree of substrate deacety-
lation. Drug treatments and/or concentrations are indicated on the
horizontal axes. WR301801 but not artemisinin exhibited dose-related
inhibition of HDAC activity in malaria (A), with an IC50 of between 1
and 10 nM. WR301801 exhibited a similar effect, with an IC50 of 10 nM
in mammalian cells (B).
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tive compound was selected for in vivo studies in the P. berghei-
mouse blood schizonticidal model. The compound was tested
from doses of 40 to 640 mg/kg/day for 3 days given once per
day by oral gavage (Table 3). Control animals typically died or
were euthanized at the moribund early endpoint between day
6 to 10 postinfection. No animals were cured using this regi-
men, although posttreatment parasitemia relative to controls
declined with dose. We attempted to induce cures through
split-dosing regimes, longer periods of administration, subcu-
taneous dosing, and administration at the time of parasite
inoculation. None of these attempts were successful. Split dos-
ing actually decreased the efficacy marginally, whereas subcu-
taneous dosing was associated with toxicity (Table 3). The
induction of clearance with the once-a-day regimen is theoret-
ically possible at the next highest dose of 1,280 mg/kg/day for
3 days based on the observed dose response (Fig. 3) but not
practical. Toxicity was observed only after subcutaneous dosing
(Table 3) and in one of five mice given a split oral dose of 130
mg/kg/day for 3 days in preliminary experiments (data not
shown). Given that the metabolic instability of WR301801 was
greater in rodent than in primate microsomes (see below) and
toxicity was not observed after once daily oral administration,
we considered a focused set of Aotus experiments to be rea-
sonable. Five Aotus monkeys infected with P. falciparum FVO,
in which an earlier course of experimental quinoline methanols
had failed to induce cures, were given WR301801 at once daily
oral doses of 8, 16, or 32 mg/kg/day for 3 days. Although
WR301801 was not effective, there did appear to be a dose-
related effect on parasitemia (Fig. 4). The 32-mg/kg/day dose
stabilized parasitemia during the treatment period despite a
relatively high starting level. In contrast, the parasitemia of
animals given lower doses increased. This is evident when
parasitemias are averaged for each dose group and normalized
relative to starting parasitemias (Fig. 4B). The 32-mg/kg/day
dosing regimen is probably equivalent to a 160-mg/kg/day dose
TABLE 3. Efficacy and toxicity of WR301801 in P. berghei-infected mice
Daily dose
(mg/kg/day) Route
No. of
days
Single (S) or
split (D)
daily dose
Fraction of
posttreatment
control
parasitemia
on day 6a
No. of animals/total no. in group
No. of
cures Toxic deaths
40 Oral 3 D 0.32 0/5 0/5
80 Oral 3 D 0.05 0/5 0/5
160 Oral 3 D 0.03 0/5 0/5
320 Oral 3 D 0.004 0/5 0/5
640 Oral 3 D 0.001 0/5 0/5
20 Oral 3 S 0.57 0/5 0/5
40 Oral 3 S 0.12 0/5 0/5
80 Oral 3 S 0.096 0/5 0/5
130 Oral 7 D 0.01 0/5 0/5
130 Subcutaneous 3 D NA 0/5 5/5 (day5)
a Calculated as the parasitemia in the treatment group on day 6/the parasitemia in control group on day 6. NA, not applicable.
FIG. 3. Dose-related parasite killing by WR301801 in vivo. When
administered in a once daily oral regimen, the fraction of parasites
remaining relative to controls declines linearly with increasing dose (40
to 640 mg/kg/day) on a log scale. A further increase of the dose to
1,280 mg/kg/day would probably result in a decline in parasitemia
below the limit of detection but is impractical.
FIG. 4. Effect of WR301801 on P. falciparum FVO in Aotus.
(A) Five Aotus monkeys previously administered a failed regimen of an
experimental quinoline methanol were given WR301801 at doses of 8,
16, or 32 mg/kg/day orally for 3 days as indicated by the black bar. Two
days after the third dose the animals were rescued with a single 20-
mg/kg dose of mefloquine, since the WR301801 treatments failed.
However, WR301801 did exhibit a dose-related effect on parasitemia.
(B) This is evident when parasitemias are averaged for each dose
group and normalized relative to the starting values.
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in mice (based on similar starting and finishing parasitemias;
see Table 6 and Fig. 4).
WR301801 metabolism-pharmacokinetic studies. The half-
lives of WR301801 in mouse and human liver microsomes were
11 and 60 min, respectively. A metabolic product was iden-
tified with a mass that is 15 atomic mass units less than
WR301801. The putative, inactive metabolite of WR301801 is
WR308301 (Fig. 5). This was later confirmed to be WR308303
by nuclear magnetic resonance analysis. This metabolite was
produced in mouse and human microsomes. This metabolite
was observed in the absence of microsomal cofactors, suggest-
ing that its metabolism was not mediated by cytochrome P450.
It was not a heat degradation product since it was not observed
after incubation in buffer at 37°C. In addition, subsequent
analyses with rhesus monkey plasma at room temperature and
at 37°C failed to show significant decay of either compound.
When evaluated for drug interaction potential in vitro,
WR301801 showed low to moderate inhibition of 1A2, 2C9,
2C19, and 2D6 (IC50s of 40, 14, 26, and 40 M, respec-
tively). The potential was more marked for 3A4 (IC50  5.7
M using two substrates). The pharmacokinetics of WR301801
administered orally and subcutaneously at 50 mg/kg was eval-
uated in mice. The plasma levels of WR301801 and its putative
metabolite WR308303 were monitored prospectively in the
same sample by using liquid chromatography-tandem mass
spectrometry. The standard curves of drug concentration ver-
sus peak area were linear within the analytical range with an r2
value of 0.99 or better. Quality control samples at 10 and 100
ng/ml were within 15 and 10% (respectively) of their predicted
values with a percent coefficient of variation (%CV) that is less
than 10%. Extracts placed in a refrigerated autosampler were
stable throughout the course of the analysis. Plasma concen-
tration-time curves are presented in Fig. 6, and the pharma-
cokinetic parameters are given in Table 4. WR301801 was
apparently adequately bioavailable since plasma levels mark-
edly exceeded the in vitro IC90, and the AUC and Cmax values
were higher than after subcutaneous dosing. The terminal half-
lives of WR301801 were approximately 3.5 and 8.5 h after oral
and subcutaneous dosing. The putative acid metabolite
WR308303 was present after both oral and subcutaneous dos-
ing (Fig. 6), but only AUC values were calculable due to
variability in the concentration-time curves, particularly after
subcutaneous dosing.
In vitro and in vivo drug combination studies. For other
treatment indications, HDACIs are being evaluated as combi-
nation agents. Using isobologram analysis, we investigated the
interaction of WR301801 with the following representative
members of several important antimalarial drug classes: me-
floquine, chloroquine, artemisinin, and azithromyicin. Para-
sites were continuously exposed to both drugs over 72 h to
mimic the likely clinical scenario where parasites are continu-
ously exposed to effective plasma concentrations of the agents
for this length of time. As can be see from Table 5, WR301801
exhibited generally antagonistic effects when combined with
these agents. In preliminary studies a similar trend toward
antagonism with atovaquone was also seen (data not shown).
WR301801 was then combined with chloroquine in an in vivo
study (Table 6). The drugs were tested alone at several differ-
ent doses and combined in two different experimental para-
digms. First, the fractional inhibitory dose of WR301801 was
diluted 1:1, 1:10, 1:100, and 1:1,000 relative to chloroquine
where the equi-active doses of the drugs alone were assumed
to be 320 mg/kg (WR301801) and 4 mg/kg (chloroquine) based
on preliminary data. Second, the mg/kg dose ratio of 1.25 at
the 1:100 dilution was maintained, but the actual doses of both
drugs given was higher. The first of these combination ap-
proaches was attempted since it is possible that only small
amounts of HDACI might be required for synergism in vivo.
The second approach was attempted because in a normal clin-
ical dosing situation it is more likely that the dose of a deployed
HDACI would be closer in absolute mg/kg terms to that of the
combination partner (see Discussion). In the dilution mode,
the combination of WR301801 and chloroquine is consistent
FIG. 5. Putative metabolism of WR301801 to the inactive metab-
olite WR308303. The metabolite was observed in in vitro microsome
experiments and in vivo in mice.
FIG. 6. Plasma concentration-time curves for WR301801 (A) and
its metabolite WR308303 (B) after the administration of WR301801
(50 mg/kg) orally and subcutaneously to mice.
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with an additive to antagonistic effect. For example, when
chloroquine at 2 mg/kg was combined with WR301801 at 160
mg/kg, the suppression of parasitemia was less than that in-
duced by chloroquine at 4 mg/kg alone. In a more normal
clinical dosing mode, cures were actually observed when both
agents were combined at a dose of 64 mg/kg chloroquine and
54 mg/kg WR301801, whereas doses of WR301801 as high as
640 mg/kg/day did not cure mice. Chloroquine doses as high as
90 mg/kg/day for 3 days are required to induce cures. Chloro-
quine is toxic in this model at doses of 160 mg/kg/day for 3 days
(data not shown).
DISCUSSION
In this study we profiled the antimalarial activity and phar-
macology of a group of phenylthiazolyl hydroxamate-based
histone deacetylase inhibitors, with a focus on the most potent
compound, WR301801. This compound exhibited an IC50 of
0.5 to 1.5 nM against several drug-resistant strains of P. falcip-
arum. Prior studies demonstrated WR301801 to be a mamma-
lian HDACI (23), an observation confirmed here (Fig. 2). Here
we show that WR301801, like SAHA, trichostatin A, and
2-aminosuberic acid analogs (1), induces hyperacetylation of P.
falciparum histones (Fig. 1) and inhibits parasite HDAC activ-
ity (Fig. 2). WR301801 has a key advantage over these other
compounds: much greater selectivity at the cellular level (Ta-
ble 7). In vivo, WR301801 was orally bioavailable, suppressed
parasitemia when given as monotherapy, and cured infections
when administered with subtherapeutic doses of chloroquine.
WR301801 exhibited a short half-life in both in vivo and in
vitro microsomal studies and appeared to be metabolized via
hydrolysis of its hydroxamate group. As outlined in Table 7,
WR301801 represents an improvement on previously de-
scribed P. falciparum HDACIs. WR301801 is by an order of
magnitude the most potent HDACI tested to date. It exhibits
markedly greater selectivity than other compounds. The in vivo
potency of WR301801 relative to apicidin and SBHA is difficult
to assess; these compounds have been tested in different ways
in each respective study (Table 7). However, WR301801 is
probably more active in vivo than apicidin, since both drugs
exhibited similar suppression of parasitemia on day 6 postin-
fection (95%), and yet apicidin was administered in a pro-
phylactic mode (starting 2 h postinfection) and given intraperi-
toneally (neither was the case for WR301801; Table 7).
WR301801 may therefore serve as a useful scaffold from which
to develop a new class of antimalarial drugs.
There is not yet a consensus on how HDACIs might hypo-
thetically be deployed as antimalarial agents. The development
of antimalarial drugs is entering a new phase. Effective arte-
misinin-based combination therapies (ACTs) have been de-
ployed (33), so the research and development focus is broad-
ening to include a wider array of malaria indications.
Medicines for Malaria Venture (31) now describes seven target
product profiles, including uncomplicated malaria, acute/
severe malaria, P. vivax radical cure, intermittent preventive
treatment (IPT) in children, IPT in pregnancy, malaria pre-
vention and standby treatment for travelers. Based on the
mechanisms of action of HDACIs in mammalian cells, use for
IPT is probably not appropriate. The prophylaxis and severe
malaria indications require specific technical attributes (rapid-
ity of action/excellent tolerability, etc.) for which there are as
TABLE 4. Pharmacokinetic parameters of WR301801 and its metabolite WR308303 after oral and subcutaneous dosinga
Parameter
Mean  SD (%CV)
WR301801 Metabolite (WR308303)
Oral Subcutaneous Oral Subcutaneous
Cmax (ng/ml) 2,500  1,100 (48) 403 431 (110) NC NC
Tmax (h) 0.83  0.29 (35) 1.3  1.5 (58) NC NC
AUC (ng  h/ml) 3,690  1,274 (35) 3,603 2,597 (72) 478 229 (48) 400  590 (150)
t1/2 (h) 3.5  0.71 (20) 8.5  0.51 (6.0) NC NC
a CV, coefficient of variation. Cmax refers to the maximum plasma concentration, and Tmax is the time at which the maximum plasma concentration occurs.
TABLE 5. Sum of FICs for WR301801 combined with
conventional antimalarials
Partner drug

FIC (n, range)a
W2 D6
Avg for all
dilutions Maximum avg
Avg for all
dilutions Maximum avg
Mefloquine 1.7 (3, 1.3–2.5) 2.1 (3, 1.5–3.2) 1.8 (3, 1.3–2.1) 2.2 (3, 1.7–2.5)
Chloroquine 1.5 (2, 1.2–1.7) 1.9 (2, 1.7–2.1) 1.5 (2, 1.5–1.5) 2.2 (2, 2.2–2.2)
Azithromycin 1.2 (3, 1.0–1.3) 1.5 (3, 1.2–1.7) 1.3 (3, 1.2–1.4) 1.7 (3, 1.5–1.9)
Artemisinin 1.7 (3, 1.7–1.8) 2.1 (3, 2.0–2.1) 1.8 (3, 1.7–2.0) 2.1 (3, 1.9–2.3)
a FICs of 0.5, 1, and 2 are normally considered to be synergistic, additive,
and synergistic, respectively. n, number of experiments.
TABLE 6. Efficacy of WR301801-chloroquine combinations on
P. berghei in mice
Dose (mg/kg/day 3) Parasitemia (%)
Curesa
WR301801 Chloroquine Day 3 Day 6
Control Control 0.46 37 0/5
None 1 0.52 41 0/5
None 2 0.43 5.0 0/5
None 4 0.36 0.004 0/5
None 8 0.21 0.001 0/5
None 16 0.26 0.000 0/5
None 64 0.38 0.002 0/5
320 None 0.52 0.107 0/5
160 None 0.64 8.8 0/5
32 None 0.38 21 0/5
3.2 None 0.64 40 0/5
0.32 None 0.62 45 0/5
160 2 0.5 0.36 0/5
32 3.6 0.44 0.08 0/5
3.2 4 0.6 0.029 0/5
0.32 4 0.72 0.024 0/5
12.8 16 0.52 0.000 0/5
52 64 0.48 0.000 3/5
a That is, the number of animals cured/total number of animals tested.
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yet insufficient data to determine whether HDACIs would be a
logical match. The uncomplicated malaria and traveler standby
treatment indications seem the most appropriate at this stage
given the results we and others have shown. If the currently
deployed ACTs fail en mass, it will likely be due to the devel-
opment of artemisinin resistance. It therefore seems appropri-
ate to explore the possibility that HDACIs might serve as a
functional replacement for artemisinin compounds in future
drug combinations regimens.
What kind of HDACI drug combination might be used in
light of the in vitro and in vivo drug combination data? In the
in vitro isobologram studies, WR301801 exhibited apparent
antagonism with chloroquine, atovaquone, azithromycin, and
mefloquine. This also appeared to be the case in vivo when the
fractional inhibitory dose of the WR301801 component of the
combination was diluted relative to choroquine. In this respect,
the in vitro data can be seen as predictive of some of the in vivo
data. If this trend remains true, it would indicate that combi-
nation of small dose of an HDACI with a clinically effective
dose of a conventional antimalarial might have limited utility.
However, there was a clear difference in outcomes when the
dose combination used approached mg/kg parity; the “64/52
mg/kg/day for 3 days” chloroquine-WR301801 combination re-
sulted in cures where 10-fold-higher doses of WR301801 were
ineffective and chloroquine doses of 90 mg/kg/day for 3 days
were required to induce cures. These data are generally sup-
portive of the use of HDACIs in future drug combinations. We
do not know how to interpret these data in the context of the
antagonism observed in vitro. The in vivo situation is compli-
cated by metabolism, species differences, and changing ratios
of WR301801 and chloroquine plasma concentrations over
time. The utility of the isobologram approach for predicting in
vivo outcomes may, perhaps unsurprisingly, be limited. Our
future combination studies will focus on mouse studies in order
to provide the rationale for a more definitive set of Aotus
experiments (discussed below).
A drug deployed for treatment of uncomplicated malaria
must be effective in an oral administration route, in a once-
daily regimen, for three consecutive days (31). The expected
cure rate is 99% (31). However, this is not the case for the
artemisinin component of ACTs administered as mono-
therapy. Artemisinin compounds administered even as a 7-day
regimen result in a 10% failure rate (33), and this failure rate
is higher with shorter regimens. However, the rapidity of action
of artemisinins allows dramatic reductions in the parasite bur-
den (33). When combined, this enhances the clinical efficacy of
their combination partner even against a background of resis-
tance (e.g., mefloquine). How then might we test the utility of
this approach for an HDACI? Experimentally, the most ap-
propriate model would be evaluation of a drug combination
against drug-resistant P. falciparum strain in Aotus monkeys.
Strains resistant to antifolates and chloroquine, but not the
currently used ACTs, have been adapted to Aotus. Therefore,
chloroquine is a logical partner drug with which to test the
hypothesis in a proof-of-principle experiment. The combina-
tion experiments described here represent the first in a series
required to establish a rationale for future Aotus testing. How-
ever, WR301801 is not the compound with which this proof of
principle should be demonstrated since the drug does not clear
parasitemia like artemisinin when used alone as monotherapy.
We would expect that WR301801 would clear parasitemias at
a dose of 1,280 mg/kg/day in mice (Fig. 4), and we know that a
dose of 32 mg/kg/day for 3 days is tolerated in Aotus (Fig. 5)
and is equivalent to 160 mg/kg/day for 3 days in mice (Table 6).
A new HDACI therefore would need to be at least eightfold
more potent than WR301801 in vivo and similarly well toler-
ated to be considered for progression to Aotus studies.
From a medicinal chemistry perspective, much can be done
to meet this objective. HDACIs are generally considered to
have a cap group, linker region, and zinc binding group (ZBG;
see Fig. 7). WR301801 is already as potent or more potent than
TABLE 7. Potency, selectivity, and in vivo efficacy of WR301801 compared to other HDACIs
Compound Potency(nM)a SI (cells) In vivo activity; 50% curative dose (CD50) in mg/kg/day
Source or
reference
WR301801 0.6 1,000 CD50  640 mg/kg/day for 3 days perorally (monotherapy
treatment); CD50 	 52 mg/kg/day for 3 days perorally
(combination treatment)
This study
2ASA analogs 13 5–118 NTd 1
YC-V-40 17 60 NT 9
Trichostatin A 11 25 NT 1, 2
SAHA 110 22 NT This study
Apicidinb 125 	1 CD50  100 mg/kg/day for 3 days intraperitoneally (split daily
dose, monotherapy prophylactic mode)
11
SBHA 1,300 230c CD50  400 mg/kg/day for 3 days intraperitoneally (split
dose, monotherapy treatment)
2, 4
a That is, the lowest IC50.
b The MIC was reported as 125 mg/ml. The SI is approximately 1 since the reported activity against mammalian HDAC is 50 to 100 nM.
c Based on a reported IC50 of 300 M against mammalian cells.
d NT, not tested.
FIG. 7. Structure of YC-2-88 in the context of a typical HDACI.
HDACIs typically incorporate a ZBG and cap groups separated by a
linker region.
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existing antimalarials and is relatively selective at a whole-cell
level (discussed in more detail below). Therefore, further de-
rivatization of the head or linker regions to yield these prop-
erties may not be productive. WR301801 appears to be bio-
available. Thus, our hypothesis is that metabolic instability,
mediated through hydrolysis of the hydroxamate group, is one
of the reasons for the lack of desired efficacy in vivo. There are
two logical approaches to address this deficiency. First, the
half-life of WR301801 in mouse microsomes in vitro is mark-
edly shorter than that of SAHA (data not shown), despite the
fact that both compounds contain a hydroxamate ZBG. There-
fore, a spectrum of metabolic stability may exist within this
class of compounds, so WR308298, WR308291, WR308296,
and WR308294 may be worth testing in vivo if it turns out they
have greater metabolic stability in vitro than WR301801. Al-
ternatively, it may be worth attempting to replace the hydrox-
amate moiety with an alternative ZBG. This approach has
been used successfully by our group for alternate indications
(8, 22).
We have not yet considered the issue of the mechanism of
action, toxicity, and selectivity in detail. Earlier studies have
shown that WR301801 is a nM inhibitor of mammalian HDAC
(9, 23). This was confirmed in a functional assay here (Fig. 2).
Putatively, this will also be the case in P. falciparum, as sug-
gested indirectly by the hyperacetylation and functional data
reported here (Fig. 1 and 2). As with most antimalarial drugs,
it is likely that WR301801 will also exhibit additional mecha-
nisms of action. The issue of the selectivity of HDACIs is
complicated. There are 11 zinc-based isoforms of mammalian
HDAC and at least two class I/II HDACs are expressed in
blood-stage P. falciparum parasites (5, 18, 38). Development of
an HDACI selective for malaria parasites at the enzymatic
level could therefore be a daunting task, although recent in
silico modeling studies have provided useful information for
rational development of new compounds designed to target P.
falciparum HDAC-1 (1). The HDACIs in clinical development
do not target the known mammalian isozymes with any great
selectivity (38). Rather, their selectivity is based on the biolog-
ical context; cancer cells are thought to be more vulnerable to
intermittent HDAC inhibition than normal cells. Similarly, in
our view, selectivity of HDACIs for infectious diseases should
be determined at the cellular level rather than enzyme level. In
this respect, WR301801 exhibits suitable selectivity. Our in vivo
and pharmacokinetic studies offer some insights into the toxi-
cology of the compound in vivo. Substantial toxicity was ob-
served only after subcutaneous dosing. The half-lives of
WR301801 after oral and subcutaneous doses of 50 mg/kg
were 3.5 and 8.5 h, respectively (Table 4). This suggests that
the duration of exposure may contribute to toxicity. It will be
important to determine whether this is the case in any new
series of more metabolically stable HDACIs.
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